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Abstract
Aims/hypothesis Treatment with the α3β4 nicotinic acetylcholine receptor (nAChR) agonist, 1,1-dimethyl-4-
phenylpiperazinium iodide (DMPP), improves glucose tolerance in diet-induced obese (DIO) mice, but the physiological and
molecular mechanisms are unknown.
Methods DMPP (10 mg/kg body weight, s.c.) was administered either in a single injection (acute) or daily for up to 14 days
(chronic) in DIO wild-type (WT) and Chrnb4 knockout (KO) mice and glucose tolerance, tissue-specific tracer-based glucose
metabolism, and insulin signalling were assessed.
Results In WT mice, but not in Chrnb4 KO mice, single acute treatment with DMPP induced transient hyperglycaemia,
which was accompanied by high plasma adrenaline (epinephrine) levels, upregulated hepatic gluconeogenic genes, and
decreased hepatic glycogen content. In contrast to these acute effects, chronic DMPP treatment in WT mice elicited
improvements in glucose tolerance already evident after three consecutive days of DMPP treatment. After seven days of
DMPP treatment, glucose tolerance was markedly improved, also in comparison with mice that were pair-fed to DMPP-
treated mice. The glycaemic benefit of chronic DMPP was absent in Chrnb4 KO mice. Chronic DMPP increased insulin-
stimulated glucose clearance into brown adipose tissue (+69%), heart (+93%), gastrocnemius muscle (+74%) and
quadriceps muscle (+59%), with no effect in white adipose tissues. After chronic DMPP treatment, plasma adrenaline
levels did not increase following an injection with DMPP. In glucose-stimulated skeletal muscle, we detected a decreased
phosphorylation of the inhibitory Ser640 phosphorylation site on glycogen synthase and a congruent increase in glyco-
gen accumulation following chronic DMPP treatment.
Conclusions/interpretation Our data suggest that DMPP acutely induces adrenaline release and hepatic glycogenolysis,
while chronic DMPP-mediated activation of β4-containing nAChRs improves peripheral insulin sensitivity independent-
ly of changes in body weight via mechanisms that could involve increased non-oxidative glucose disposal into skeletal
muscle.
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BAT Brown adipose tissue
CHRNB4 Neuronal acetylcholine receptor subunit β-4
DIO Diet-induced obese
DMPP 1,1-Dimethyl-4-phenylpiperazinium iodide
eWAT Epididymal white adipose tissue
GSK3 Glycogen synthase kinase 3
3H-2-DG 3H-labelled 2-deoxy-glucose
3H-2-DG-6-P 3H-2-DG-6-phosphate
iWAT Inguinal white adipose tissue
KO Knockout
nAChR Nicotinic acetylcholine receptor
PAS Phospho Akt substrate
TBC1D TBC1 domain family member
WAT White adipose tissue
WT Wild-type
Introduction
Obesity and associated metabolic disorders, such as type 2
diabetes, are major public health issues [1]. Considerable
preclinical progress has been undertaken to tackle the obesity
and type 2 diabetes pandemics, using different pharmacolog-
ical strategies [2, 3]. Recently, the activation of central nico-
tine receptors has been suggested as a promising target to
reduce food intake [4]. The nicotinic acetylcholine receptors
(nAChRs) comprise several homo- or heteropentamers
containing α subunits (CHRNA1-7 and CHRNA9-10) and/
or β subunits (CHRNB1-4) [5]. Mineur et al have shown that
pharmacological targeting of central nAChRs with nicotinic
agonists can suppress food intake in mice [4]. In line with this,
in humans, inhalation of nicotine-dense tobacco smoke is
associated with a lower body weight, while smoking cessation
is accompanied by body weight gain [6, 7]. However, inhala-
tion of the broad nAChR-agonist nicotine with smoking is
also associated with an increase in cancer risk [8, 9], non-
alcoholic fatty liver disease [10], and peripheral insulin resis-
tance [11] in humans.
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We have recently shown that selective targeting of the
α3β4 nAChRs with 1,1-dimethyl-4-phenylpiperazinium
iodide (DMPP) reduces food intake and lowers body weight
in diet-induced obese (DIO) mice [2]. In addition, we made
the serendipitous observation that DMPP treatment for 7 days
also robustly improved glucose tolerance. Even when admin-
istered at doses below the threshold needed to reduce body
weight, DMPP ameliorated an impaired glucose tolerance [2].
This suggests that DMPP-mediated α3β4 nAChR engage-
ment per se improves glucose tolerance; however, this has
not been formally tested. In addition, the physiological and
molecular mechanisms underpinning the glycaemic benefit
of DMPP are unknown. For instance, it remains to be clarified
whether DMPP improves glucose tolerance because of
enhanced insulin secretion or because of effects on peripheral
insulin sensitivity (or both). Furthermore, it is unknown
whether DMPP-mediated improvements in glucose tolerance
require functional α3β4 nAChRs. Therefore, we here
assessed the glucometabolic effects of DMPP in ad libitum-
fed DIO mice, in DIO mice pair-fed to DMPP-treated mice,
and in knockout (KO) DIO mice that lack β4 nAChR (neuro-
nal acetylcholine receptor subunit β-4 [CHRNB4], which is
encoded by Chrnb4).
Methods
Mice for pharmacological studies For wild-type (WT) mouse
studies, male C57BL/6J mice were obtained from Janvier
Labs (Le Genest Saint Isle, France). Chrnb4 KO mice were
generated as described previously [12]. HeterozygousChrnb4
KOmice on a C57BL/6J backgroundwere kindly provided by
U. Maskos (Institut Pasteur, Paris, France) and bred in-house
at the Helmholtz Zentrum München, Neuherberg, Germany.
HomozygousChrnb4KO andWTmice were used to generate
colonies ofChrnb4KO andWTmice. All mice were switched
from a regular chow diet to a high-fat, high-sucrose diet
(D12331; Research Diets, New Brunswick, NJ, USA) at an
age of 8 weeks, with ad libitum access to water and diet. Mice
were maintained at 23°C ambient temperature under specific
pathogen-free conditions at constant humidity and on a 12 h
light–dark cycle.
Pharmacological intervention studies Interventions were
performed in DIO mice weighing ~50 g. DIO mice are used
as a model for obesity and insulin resistance associated with
the human metabolic syndrome, an established risk factor for
development of type 2 diabetes [13]. Mice were randomly
assigned to pharmacological treatment groups based on body
weight or ad libitum-fed blood glucose. For the pair-feeding
study, daily food of pair-fed mice was matched to food intake
of DMPP-treatedmice. The experimenters were not blinded to
the intervention groups. DMPP (D5891, Sigma-Aldrich,
Munich, Germany) was administered in saline (NaCl 0.9%)
at 10 mg/kg body weight with the vehicle control group
receiving 1% DMSO in saline. Compounds were adminis-
tered s.c. at a volume of 5 μl/g body weight. In the acute
set-up, food was removed and ad libitum blood glucose was
determined at 07:00 hours in blood sampled from the tail vein
and measured using handheld glucometers (Abbott,
Wiesbaden, Germany). Blood for insulin measurements was
collected at time points as indicated in the figures by bleeding
mice from the tail vein into EDTA-coated microvette tubes
(Sarstedt, Nümbrecht, Germany). For assessment of plasma
catecholamines after acute DMPP, blood was collected into
EDTA-coated microvette tubes (Sarstedt) 80 min after
DMPP injection. For chronic studies, unless stated otherwise,
DMPP was injected s.c. daily in the late afternoon. For
glucose tolerance tests, mice were fasted for 6 h (starting at
07:30 hours) and received i.p. injections of glucose at
1.75 g/kg body weight. In the chronic pair-feeding and
Chrnb4 KO studies, glucose tolerance tests were performed
on day 7. On day 10 (i.e. after 10 days of daily DMPP injec-
tions) mice were fasted for 6 h (starting at 07:30 hours),
glucose (1.75 g/kg body weight) was i.p. injected, and after
30 min mice were euthanised by cervical dislocation and
blood and tissues were quickly collected.
For measurement of plasma catecholamines after 7 days of
daily DMPP injections, blood was collected 80 min after last
compound injections (on day 8) into EDTA-coated microvette
tubes (Sarstedt). In the chronic studies lasting for 14 days,
mice were injected with vehicle or DMPP and fasted 2 h prior
to killing. All animal experimentations were approved and
conducted in accordance to the Danish Animal
Experimentation Inspectorate and Animal Ethics Committee
of the Government of Upper Bavaria, Germany.
Plasma variables The collected blood was immediately kept
on ice and centrifuged for 10 min at 3000 g and 4°C.
Plasma was stored at −20°C until further analysis. Plasma
insulin levels were analysed using a commercially available
ELISA kit (Alpco Diagnostics, Salem, NH, USA) following
the manufacturers’ instructions. Plasma catecholamines were
analysed and detected with an HPLC system coupled with
an electrochemical detector (EcD) as described previously
[14]. The sample clean-up was performed according to the
protocol described by Recipe (Recipe, Munich, Germany).
The Recipe ClinRep complete kit contains all necessary
chemicals and materials for the extraction. The limited
amount of plasma per sample necessitated some modifica-
tions from the standard protocol. Therefore, 30–40 μl of
plasma was diluted with 40 μl of water and 10 μl of internal
standard was added. Upon vigorous mixing, the samples
were charged on the sample preparation column. The
column was shaken for 10 min and the solvent was removed
on a vacuum manifold. The column was washed three times
with 1 ml washing solution to remove interfering compo-
nents. After drying the column, the elution reagent was
added (140 μl). The catecholamines were eluted from the
extraction column via centrifugation and 20 μl of the eluate
was injected into the HPLC-EcD system.
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Gene expression analysis For tissue collection, mice were
either euthanised using CO2 or killed by cervical dislocation.
Tissues were extracted and immediately kept on dry ice or
liquid nitrogen and stored at −80°C until further analysis.
For gene expression analysis, liver RNA was isolated using
the TRIzol-based RNeasy Kit (Qiagen, Hilden, Germany)
according to the manufacturers’ instructions. cDNA was
synthesised from total RNA using QuantiTect Reverse
Transcription Kit (Qiagen). Gene expression profiles were
assessed in the liver with the quantitative real-time PCR tech-
nique using SYBR green (Thermo Fisher Scientific, Erlangen,
Germany). Relative gene expression was normalised to the
reference gene Hprt. Primer sequences used are listed in
alphabetical order in electronic supplementary material
(ESM) Table 1.
Tissue glycogen Hepatic and muscle glycogen was measured
in 20–40 mg of tissue using a commercially available kit
(Biovision, Milpitas, CA, USA) following the manufacturers’
instructions.
Western blot analyses Approximately 25 mg of quadriceps
muscle was homogenised (Tissue Lyzer II, Qiagen) in ice-
cold buffer as described previously [15]. Homogenates were
rotated end-over-end for 1 h and lysate supernatants were
collected by centrifuging for 20 min at 16,000 g and 4°C.
Protein concentrations were assessed using the bicinchoninic
acid method (Pierce Biotechnology, Rockford, IL, USA).
Samples were heated (96°C) in Laemmli buffer before being
subjected to SDS-PAGE and semi-dry blotting. The primary
antibodies used were from Alpha Diagnostics (San Antonio,
TX, USA) (hexokinase II #HXK23-A [1:1000], RRID
AB_2117140); Cell Signaling Technology (Danvers, MA,
USA) (Akt2 #3063 [1:1000], RRID AB_2225186; p-Akt
Thr308 #9275 [1:1000], RRID AB_329828; p-Akt Ser473
#9271 [1:1000], RRID AB_329825; phospho Akt substrate
[PAS] #9611 [1:500], RRID AB_330302; p-TBC1 domain
family member [TBC1D] 1 Thr596 #6927 [1:1000], RRID
AB_10828720); Thermo Fisher Scientific (Waltham, MA,
USA) (GLUT4 #PA1-1065 [1:1000], RRID AB_2191454);
Millipore (Burlington, MA, USA) (TBC1D4 #07-741
[1:1000], RRIDAB_492639). TBC1D1, p-glycogen synthase
Ser640, and glycogen synthase were kindly donated by G.
Hardie, University of Dundee, UK. Secondary antibodies
were from Jackson ImmunoResearch (Ely, UK) (1:3000).
Membranes were probed with enhanced chemiluminescence
(ECL+; Amersham Biosciences, Piscataway, NJ, USA) and
immune complexes were visualised using ChemiDoc MP
Imaging System (Bio-Rad Laboratories, Hercules, CA,
USA). Signals were quantified (Image Lab, Bio-Rad
Laboratories) and expressed as arbitrary units.
In vivo 2-deoxy-glucose clearance and glucose incorporation
into glycogen For assessment of glucose-induced glucose
clearance and glucose incorporation into glycogen, glucose
at 1.75 g/kg body weight was i.p. injected at 10 μl/g body
weight together with 3H-labelled 2-deoxy-glucose (3H-2-
DG) (2.22 MBq/ml) and D-6-14C-labelled glucose
(0.185 MBq/ml), respectively, to mice treated with DMPP
daily for 8 days and fasted for 6 h. Blood glucose was
measured at the indicated time points using a handheld
glucometer (Arseus Medical, Bornem, Belgium). For anal-
ysis of 3H-2-DG clearance in indicated tissues, plasma 3H
activity was measured at 10, 20, and 40 min in 5 μl of
blood by scintillation counting and systemic 3H-2-DG
exposure estimated by the trapezoidal method. A 25 mg
sample of each tissue was used to determine the accumu-
lation of 3H-2-DG-6-phosphate (3H-2-DG-6-P) by the
precipitation method [16]. Glucose clearance was calculated
by dividing tissue 3H-2-DG-6-P counts by systemic 3H-2-
DG exposure [17]. For muscle glucose incorporation into
glycogen, ~15 mg of gastrocnemius muscle was weighed
out, mixed with 1 ml of 1 mol/l NaOH, and boiled at
99.5°C for 30 min. To facilitate the precipitation of glyco-
gen, 170 μl of glycogen (4 mg/ml, G-8876, Sigma-Aldrich)
was added and samples mixed. Ice-cold 96% ethanol
(800 μl) was added, samples mixed, and stored at −20°C
overnight. Samples were centrifuged at 1200 g for 15 min,
the ethanol was removed, and the pellet was re-suspended
in 2 ml of ice-cold 96% ethanol. After another centrifuga-
tion at 1200 g for 15 min, ethanol was removed and 550 μl
H2O was added to dilute the pellet; 525 μl of the sample
was added to 3 ml of scintillation fluid, vigorously mixed,
and analysed by scintillation counting for 14C (Packard
TriCarb 2900TR, Perkin-Elmer, Boston, MA, USA).
Glucose incorporation into glycogen was expressed as 14C
glucose counts in the glycogen precipitated.
Statistics Data were analysed in GraphPad Prism (versions 6
and 8; GraphPad Software, San Diego, CA, USA). The types
of statistical tests performed are outlined in the figure legends.
A p value ≤0.05 was considered statistically significant. All
results are presented as mean ± SEM.
Results
DMPP has acute hyperglycaemic effects, but exerts glycaemic
benefits after 3 days of daily administration in DIO mice A
single s.c. administration of DMPP (10 mg/kg body weight)
increased ad libitum-fed blood glucose by ~200% in compar-
ison with vehicle in DIO mice, with a peak at ~2 h after
treatment and a return to baseline after 5 h (Fig. 1a). This
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short-term hyperglycaemic effect of DMPP was absent in
mice that globally lack the β4 subunit of the α3β4 nAChRs
(Chrnb4 KO mice) (ESM Fig. 1a, b). Despite its short-term
hyperglycaemic effect, a single treatment with DMPP did not
affect glucose tolerance in DIOmice the following day (day 1)
(Fig. 1b). After two days of daily DMPP administration, injec-
tion of DMPP had no effect on ad libitum-fed blood glucose
(Fig. 1c) and already after the third DMPP injection (day 3),
glucose tolerance in DIO mice was significantly improved
(Fig. 1d).
DMPP acutely increases circulating adrenaline and lowers
hepatic glycogen content The transient hyperglycaemia
observed in DIO mice after the first single DMPP injec-
tion was associated with a fourfold increase in plasma
adrenaline 80 min after injection (p ≤ 0.01), while circu-
lating noradrenaline (Fig. 2a) and insulin (Fig. 2b) were
unaltered. Adrenaline is known to increase hepatic
glucose output [18] and, in agreement, hepatic glycogen
content in DMPP-treated mice was 36% lower 150 min
after injection compared with vehicle (Fig. 2c; p ≤ 0.01).
Liver glycogen breakdown was accompanied by an
increase in the expression of hepatic genes involved in
gluconeogenesis 150 min after administration (Fig. 2d).
After 7 days of daily DMPP treatment (chronic), DMPP
injection on day 8 did not have effects on circulating
adrenaline levels (ESM Fig. 2b) and DMPP administra-
tion did not induce changes in hepatic gluconeogenic gene
expression after 14 days of treatment (ESM Fig. 2c).
Chronic DMPP improves glucose tolerance independent of
changes in body weight, via CHRNB4, and without increasing
insulin secretion Chronic treatment with DMPP improves
glucose tolerance in DIO mice [2]. However, it is
unknown whether this: (1) occurs independently of
changes in body weight; (2) requires functional α3β4
nAChRs; and (3) is the consequence of increased insulin
secretion or improved peripheral insulin sensitivity. We
therefore assessed glucose tolerance in vehicle- and
DMPP-treated mice, as well as in vehicle-treated mice
that were pair-fed to the DMPP group. Ten days of
DMPP administration induced a significant reduction in
food intake and body weight compared with vehicle-
treated mice (Fig. 3a, b). Pair-fed vehicle-treated mice
lost a similar amount of body weight as the DMPP-
treated mice (~5%). Fasted blood glucose levels on day
7 and on day 10 were not different among the three
groups (Fig. 3c, d). However, glucose tolerance was
robustly improved in DMPP-treated mice compared with
both vehicle-treated and pair-fed vehicle-treated mice
(Fig. 3c, d).
Second, we utilised Chrnb4 KO mice to investigate
whether glycaemic benefits of DMPP require β4-
containing nAChRs. In DIO WT mice, but not DIO
Chrnb4 KO mice, daily administration of DMPP for
10 days led to significantly lower body weight and food
intake (Fig. 3f, g). Genotype or DMPP treatment did not
affect fasted blood glucose levels on day 7 and on day 10
(Fig. 3h, i), but DMPP significantly improved glucose
tolerance in DIO WT mice, yet failed to do so in
Chrnb4 KO mice (Fig. 3h, i).
Third, we measured plasma insulin levels 30 min after i.p.
glucose injection and detected no differences in circulating
insulin in DMPP-treated mice compared with control mice
(Fig. 3e, j), suggesting that improvements in glucose tolerance
are not mediated by augmented insulin secretion.
Chronic DMPP increases glucose uptake in brown adipose
tissue and striated muscles After 8 days of daily DMPP
administration, improved glucose tolerance (Fig. 4a)
was associated with increased glucose disposal into
brown adipose tissue (BAT) (+69%), gastrocnemius
muscle (+74%), quadriceps muscle (+59%), and heart
(+93%) with no effects in inguinal or epididymal white
adipose tissue (iWAT and eWAT) (Fig. 4b–g). In accor-
dance with what we observed above, chronic DMPP did
not increase glucose-stimulated plasma insulin levels
(ESM Fig. 2a).
DMPP has no effect on Akt signalling, but increases glycogen
content in skeletal muscle Given the quantitative importance
of skeletal muscle in whole-body postprandial glucose dispos-
al [19, 20], we investigated canonical insulin signalling in
in vivo glucose-stimulated quadriceps muscle after 8 days of
daily DMPP treatment. Insulin-responsive signalling proteins
Akt, TBC1D1, and TBC1D4 displayed similar phosphoryla-
tion states in DMPP- and vehicle-treated mice (Fig. 5a–c) and
the protein abundance of GLUT4 was also comparable
between the two groups (Fig. 5a, c). Notably, however, we
observed a reduction in the Ser640 phosphorylation site on
glycogen synthase in DMPP-treated mice (Fig. 5a, b).
Glycogen synthase Ser640 phosphorylation suppresses glyco-
gen synthase activity [21, 22], suggesting an increased glyco-
gen synthase activity after chronic DMPP treatment.
Congruent with these data, we observed apparently augment-
ed incorporation of labelled glucose into glycogen, although
this failed to reach statistical significance (Fig. 5d, p = 0.064)
and significantly increased skeletal muscle glycogen content
in DMPP-treated mice, also compared with pair-fed mice with
a similar loss in body weight (Fig. 5e, f, p ≤ 0.05). Conversely,











































































































































DIO WT − Vehicle
DIO WT − DMPP (10 mg/kg)
Fig. 2 Acute DMPP increases circulating adrenaline and induces hepatic
gluconeogenesis and glycogenolysis. (a–d) Effect of first injection of
DMPP (10 mg/kg) or vehicle in DIO WT mice on (a) plasma noradren-
aline (NAd) and adrenaline (Ad) concentrations determined in blood
collected 80 min after vehicle or DMPP was injected (n = 8); on (b)
plasma insulin concentrations in blood collected 80 min after vehicle or
DMPPwas injected (n = 8); on (c) liver glycogen at 150 min after vehicle
or DMPP injection (n = 4–5); and on (d) expression of indicated genes in
the liver at 150 min after vehicle or DMPP injection (n = 4–5). All data
are presented as mean ± SEM. Data were probed with two-tailed
Student’s t tests, comparing the means of vehicle and DMPP; *p ≤ 0.05,
**p ≤ 0.01 compared with vehicle. ww, wet weight






















































































































































































DIO WT − Vehicle DIO WT − DMPP (10 mg/kg)
Fig. 1 DMPP acutely elicits hyperglycaemia, while chronically it
improves glucose tolerance. (a) Effect of first injection (i.e. day 0) of
DMPP (10 mg/kg) or vehicle injected at time point 0 min on blood
glucose excursion with AUC in DIO WT mice. (b) Glucose tolerance
with incremental AUC (iAUC) determined 24 h after the first injection
(i.e. day 1) of DMPP or vehicle. (c) Effect of the third injection (i.e. day 2)
of DMPP or vehicle on blood glucose excursion and AUC. (d) Glucose
tolerance with iAUC determined 18 h after the third daily injection (i.e.
day 3) of DMPP or vehicle. All data are presented asmean ± SEM (n = 7–
8). Data in line graphs were assessed by two-way repeated measures
ANOVA (time × drug) with a subsequent Bonferroni post hoc test. Data
in bar graphs were probed with two-tailed Student’s t tests, comparing the
means of vehicle and DMPP; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
compared with vehicle
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Discussion
We here show that DMPP engages β4-containing nAChRs to
improve glucose tolerance in obesemice after only a few days of
administration. This glycaemic benefit of DMPP occurs inde-
pendent of changes in body weight and by enhancing peripheral
insulin sensitivity. DMPP treatment increased in vivo insulin-
stimulated glucose clearance selectively into BAT, skeletal













































































































































































































































































































DIO WT − Vehicle/Ad lib
DIO WT − Vehicle/Pair-fed
DIO WT − DMPP (10 mg/kg)
DIO WT − Vehicle
DIO Chrnb4 KO − Vehicle
DIO WT − DMPP (10 mg/kg)






Fig. 3 Chronic DMPP improves glucose tolerance independent of body
weight loss and specifically via CHRNB4. (a, b) Body weight loss (in %)
and cumulative food intake (in g) of DMPP-treated and vehicle-treated
DIO WT mice with either ad libitum (Ad lib) food access or pair-fed to
mice receiving 10 mg/kg DMPP for 10 days. (c) Glucose tolerance with
incremental AUC (iAUC) conducted 18 h after the seventh injection of
daily vehicle or DMPP (i.e. day 7). (d) Plasma glucose (at 0 and 30 min)
and (e) plasma insulin at 30 min after i.p. injection of glucose (injected at
time point 0 min), 18 h after the tenth injection of daily vehicle or DMPP
(i.e. day 10). (f, g) Body weight loss (in%) and cumulative food intake (in
g) in DIO WT or Chrnb4 KO mice receiving vehicle or DMPP. (h)
Glucose tolerance with respective iAUC 18 h after seventh injection of
daily vehicle or DMPP. (i) Plasma glucose (0 and 30 min) and (j) plasma
insulin at 30 min after i.p. injection of glucose (injected at time point
0 min) 18 h after tenth injection of daily vehicle or DMPP. All data are
presented asmean ± SEM; (n = 7–8). Data in line graphswere assessed by
two-way repeatedmeasures ANOVA (time × drug) within genotypeswith
a subsequent Bonferroni post hoc test. Data in (e) and bar graph in (c)
were assessed by one-way ANOVA, and with a subsequent Bonferroni
post hoc test (for c). Data in (j) and in the bar graph in (h) were assessed
with two-tailed Student’s t tests within the genotypes. *p ≤ 0.05, **p ≤
0.01, ***p ≤ 0.001 for vehicle compared with DMPP; †p ≤ 0.05, ††p ≤
0.01, †††p ≤ 0.001 for vehicle compared with pair-fed; ‡p ≤ 0.05, ‡‡‡p ≤
0.001 for pair-fed compared with DMPP; §p ≤ 0.05, §§p ≤ 0.01, §§§p ≤
0.001 for vehicle compared with DMPP within WT
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DIO WT − Vehicle
DIO WT − DMPP (10 mg/kg)
Fig. 4 Chronic DMPP selectively increases glucose clearance in the BAT
and the muscles. (a) Glucose excursion after injection with glucose 18 h
after the eighth injection of daily DMPP (10 mg/kg) or vehicle in DIO
WT mice. Glucose clearance into the (b) BAT, (c) gastrocnemius
(Gastroc) muscle, (d) quadriceps (Quad) muscle, (e) heart, (f) iWAT,
and (g) eWAT. All data are presented as mean ± SEM (n = 7). Data in
line graph in (a) were assessed by two-way repeated measures ANOVA
(time × drug) with a subsequent Bonferroni post hoc test. All other data
(b–g) were probed with two-tailed Student’s t tests, comparing the means
of vehicle and DMPP. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 for the effect
of drug at the indicated time point or, in bar graphs, compared with
vehicle
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muscle, and the heart, but not into WAT. In skeletal muscle,
canonical insulin signalling for glucose uptake was not altered
by DMPP, while inhibitory glycogen synthase phosphorylation
was decreased and muscle glycogen content increased.
DMPP has previously been shown to lower body weight and
improve glucose tolerance [2], yet it was unclear whether the
glycaemic benefit is secondary to the decrease in body weight.
By pair-feeding mice to DMPP-treated mice we show that
DMPP lowers body weight primarily by inhibiting food intake,
as the pair-fed vehicle-treated and DMPP-treated mice lost simi-
lar amounts of bodyweight. In agreement, it has previously been
shown that DMPP does not increase energy expenditure in DIO
WT mice during three days of daily administration [2]. Most
importantly, we demonstrate that DMPP improves glucose toler-
ance via mechanisms independent from the moderate decrease
in body weight. Notably, in contrast to DMPP-treated mice, the
~5% body weight loss in pair-fed mice was not sufficient to
ameliorate the diet-induced glucose intolerance. To determine
whether these pronounced anorectic and glycaemic effects of
DMPP depend on nicotinic receptor signalling, we assessed
chronic DMPP in DIO Chrnb4 WT and KO mice and found
that both require intact β4-containing nAChRs. Although this
does not prove that the effects are mediated solely by α3β4
nAChRs, these data emphasise an important degree of specific-
ity of DMPP, especially in contrast to the broad nAChR-agonist
nicotine [23–26].
Subsequently, we aimed to understand how DMPP
improves glucose tolerance, by assessing glucose clearance
measurements with radioactive tracers. This demonstrated that
DMPP promotes glucose disposal into selective peripheral
tissues. There are several indications that this effect, as well
as the improvements in glucose tolerance, are not due to
increased insulin secretion. First, plasma insulin was not higher
30 or 40 min after glucose injection in DMPP-treated mice. It
remains possible that earlier differences in insulin levels were
missed. Second, proximal insulin signalling in the form of Akt
phosphorylation and downstream Akt activity proxies were
similar between vehicle- and DMPP-treated muscles, suggest-
ing that the tissue was exposed to comparable amounts of
circulating insulin. Finally, if higher insulin levels/secretion
were behind the enhanced glucose disposal, we would have
expected augmented glucose disposal into all insulin-
responsive tissues, but this was not the case. Instead, DMPP-
treated mice exhibited increased glucose-mediated glucose
clearance selectively into muscle, heart, and BAT, but not into
subcutaneous or visceral WAT. The increase in BAT glucose
clearance might be related to the previous observation that
DMPP selectively induced protein expression of uncoupling
protein 1 (UCP1) in BAT, but not in the iWATof mice housed
at thermoneutrality [2]. Of particular translational relevance
could be the increase in muscle glucose uptake as the skeletal
muscle comprises ∼40% of total body mass and is the key
tissue for postprandial glucose disposal in humans [20].
Chronic DMPP treatment decreased Ser640 phosphorylation
of glycogen synthase in muscle. In general, increased phos-
phorylation suppresses glycogen synthase activity, whereas a
decrease in phosphorylation increases glycogen synthase activ-
ity [27, 28]. The Ser640 site has been proposed to play an
important role in the regulation of glycogen synthase [21, 22,
29] and thus our data indicate that increased glycogen synthase
activity with DMPP treatment augments non-oxidative glucose
disposal in muscle. In support of this notion, muscle glycogen
content was increased and glucose incorporation into glycogen
in chronic DMPP-treated DIO WT mice was augmented;
however this difference did not reach statistical significance.
It remains to be clarified how glycogen synthase phosphoryla-
tion is modified by DMPP. The Akt–glycogen synthase kinase
3 (GSK3) signalling axis is known to regulate glycogen
synthase phosphorylation, including the Ser640 residue [22,
30, 31]. In the presence of insulin, Akt inhibits GSK3 activity
towards glycogen synthase, resulting in less phosphorylation
of glycogen synthase to promote glycogen storage [32, 33].
However, since chronic DMPP did not alter Akt activity, other
pathways are likely to be responsible for the decreased glyco-
gen synthase phosphorylation in skeletal muscle. A potential
signalling pathway could involve protein phosphatase 1, which
can dephosphorylate glycogen synthase [34, 35].
glycaemic benefit [36]. Our data suggest that the acute
hyperglycaemic effect of DMPP is mediated through a β4
nAChR-induced release of adrenaline. Notably, α3β4
nAChRs are expressed in adrenaline-releasing chromaffin cells
of the adrenal medulla [37–39]. Adrenaline is known to trigger
hepatic gluconeogenesis and glycogenolysis [40, 41]. In agree-
ment, we found that acute DMPP administration in DIO WT
mice potently induced hepatic gluconeogenic gene expression
and that liver glycogen stores were reduced. Vu et al previously
observed similar hyperglycaemic outcomes after treatment of
leanmice with nicotine [42]. Of note, while DMPP only elicited
increases in adrenaline secretion, nicotine increased both plas-
ma adrenaline and noradrenaline [42]. In anaesthetised dogs,
infusion of noradrenaline but not adrenaline induced marked
insulin secretion under high glucose conditions [43]. This might
explain why acute nicotine treatment raised insulin levels [42]
when we observed no difference in insulin after DMPP injec-
tion. In the context of potential adverse cardiovascular effects,
the rise in adrenaline upon acute DMPP warrants clarification.
Notably, with repeated daily DMPP injections, the increase in
plasma adrenaline as well as the induction of hepatic
gluconeogenic genes was absent in the present study. In
contrast, chronic nicotine treatment in lean mice resulted in
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Fig. 5 DMPP increases non-oxidative glucose disposal in skeletal
muscle. (a–c) Representative western blots and quantification of indicat-
ed protein phosphorylation residues or total proteins, relative to total
protein, in quadriceps muscle from DIO WT mice treated as described
in Fig. 4. (d, e) [14C]Glucose incorporation into glycogen and glycogen
content in quadriceps (Quad) and gastrocnemius (Gastroc) muscles from
DIO WT mice treated as described in Fig. 4. (f) Quadriceps muscle
glycogen from vehicle-treated pair-fed (PF) and DMPP-treated mice
(10 mg/kg); and (g) from vehicle- or DMPP-treated DIO WT and
Chrnb4 KO mice (10 mg/kg). The key next to (e) applies to (b–e). All
data are presented as mean ± SEM. For (a–e) n = 7, except for DMPP-
treated quadriceps muscle in (e) for which n = 6, because of insufficient
material for one of the samples; (f) n = 8; (g) n = 7–8. Differences were
probed with two-tailed Student’s t tests for (b, c, d, f, g) comparing the
means of vehicle and DMPP. Data in (e) were analysed with two-way
repeated measures ANOVA (muscle × drug). *p ≤ 0.05, **p ≤ 0.01 for
DMPP compared with vehicle; §p = 0.064 for DMPP compared with
vehicle; ¶p ≤ 0.05 main effect of DMPP; ‡p ≤ 0.05 vehicle-treated pair-
fed compared with DMPP. DPM, disintegrations/min; GS, glycogen
synthase; HKII, hexokinase II; RU, relative units; ww, wet weight
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The glycaemic benefit of chronic DMPP administration is
counterintuitive to the transient hyperglycaemic episode
observed following a single DMPP injection. However, there
is precedence for differing acute vs chronic effects. Glucagon,
for example, is a catabolic hormone that functions as a potent
gluconeogenic agent acutely inducing hyperglycaemia, yet
prolonged treatment with glucagon in DIO mice can result in
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